A5102019757- Dementia and Cognitive Impairment Research
- Neurological Disease Mechanisms and Treatments
- Alzheimer's disease research and treatments
- Functional Brain Connectivity Studies
- Cerebrovascular and genetic disorders
- Advanced Neuroimaging Techniques and Applications
- Cerebrovascular and Carotid Artery Diseases
- Acute Ischemic Stroke Management
- Neurological Disorders and Treatments
- Cognitive Functions and Memory
- Retinal Diseases and Treatments
- Intracerebral and Subarachnoid Hemorrhage Research
- Head and Neck Cancer Studies
- Healthcare Systems and Public Health
- MRI in cancer diagnosis
- Brain Metastases and Treatment
- Metabolomics and Mass Spectrometry Studies
- Human Health and Disease
- Retinal Imaging and Analysis
- Brain Tumor Detection and Classification
- Radiomics and Machine Learning in Medical Imaging
- Machine Learning in Healthcare
- Advanced Proteomics Techniques and Applications
- Nutritional Studies and Diet
- Oral health in cancer treatment
Chinese University of Hong Kong
2021-2025
Prince of Wales Hospital
2021-2024
Beijing Tian Tan Hospital
2021
Capital Medical University
2021
National Clinical Research Center for Digestive Diseases
2021
Abstract INTRODUCTION The prognostic utility of plasma proteomics for cognitive decline and dementia in a Southeast Asian population characterized by high cerebrovascular disease (CeVD) burden is underexplored. METHODS We examined this Singaporean memory clinic cohort 528 subjects ( n = 300, CeVD; 167, incident decline) followed‐up 4 years. RESULTS Of 1441 proteins surveyed, 12‐protein signature significantly predicted q ‐value < .05). Sixteen diverse biological processes were implicated...
The utility of retinal photography-derived aging biomarkers for predicting cognitive decline remains under-explored. A memory-clinic cohort in Singapore was followed-up 5 years. RetiPhenoAge, a biomarker, derived from photographs using deep-learning. Using competing risk analysis, we determined the associations RetiPhenoAge with and dementia, UK Biobank utilized as replication cohort. MRI markers(cerebral small vessel disease [CSVD] neurodegeneration) its underlying plasma proteomic profile...
Abstract Introduction We compared the machine learning‐derived, MRI‐based Alzheimer's disease (AD) resemblance atrophy index (AD‐RAI) with plasma neurofilament light chain (NfL) level in predicting conversion of early AD among cognitively unimpaired (CU) and mild cognitive impairment (MCI) subjects. Methods recruited participants from Disease Neuroimaging Initiative (ADNI) who had following data: clinical features (age, gender, education, Montreal Cognitive Assessment [MoCA]), structural...
Objectives: This study aims to investigate whether the machine learning algorithms could provide an optimal early mortality prediction method compared with other scoring systems for patients cerebral hemorrhage in intensive care units clinical practice. Methods: Between 2008 and 2012, from Intensive Care III (MIMIC-III) database, all monitored MetaVision system admitted were enrolled this study. The calibration, discrimination, risk classification of predicted hospital based on assessed....
Background The association between platelet endothelial cell adhesion molecule‐1 (PECAM‐1) with cerebral small‐vessel disease and cognition in dementia‐free subjects remains uninvestigated. Methods Results A prospective cohort of was recruited from memory clinics followed up for 5 years. Annual neurocognitive assessments twice‐yearly brain magnetic resonance imaging scans were performed. Associations baseline plasma PECAM‐1 levels disease, cognitive decline (Montreal Cognitive Assessment...
Pilot study showed that Alzheimer's disease resemblance atrophy index (AD-RAI), a machine learning-derived MRI-based neurodegeneration biomarker of AD, achieved excellent diagnostic performance in diagnosing AD with moderate to severe dementia.
Alzheimer's disease-resemblance atrophy index (AD-RAI) is a machine-learning derived MRI-based brain biomarker that valid in predicting cognitive decline subjects with AD. We investigated the performance of AD-RAI long-term stroke or transient ischemic attack (TIA). recruited consecutive dementia-free stroke/TIA who had MRI at baseline (i.e., within 3-6 months after event) and data both 3 years. defined as an increase clinical dementia rating scale from 0 to 0.5 above 1 years when compared...
Abstract Background The prognostic performance of plasma proteomics for longitudinal changes in (i)cognition (ii)neuropsychiatric symptomatology and (iii)neuroimaging outcomes within South East Asia, where prevalence cerebrovascular disease is high, remains un‐investigated. Methods A prospective cohort Singaporean memory clinic attendees was followed‐up 4 years. Annual neurocognitive neuropsychiatric assessments were performed alongside 2‐yearly brain magnetic resonance imaging (MRI) scans....
Abstract Background Alzheimer’s disease (AD) resemblance atrophy index (AD‐RAI) is a novel MRI‐based machine‐learning derived biomarker for AD that valid in the detection of early AD. We aimed to investigate association between serial change AD‐RAI and cognitive progression overtime among cognitively unimpaired (CU) mild impairment (MCI) subjects with without A+T+ (i.e., Aß+ Tau+) compare it other conventional MRI biomarkers hippocampal volume (HV), fraction (HF), brain parenchymal (BPV)...
Abstract Background Alzheimer’s disease (AD) resemblance atrophy index (AD‐RAI) is an MRI‐based machine learning‐derived composite reflecting the multi‐region severity of AD. We investigated association between serial change AD‐RAI and cognitive progression overtime among unimpaired (CU) mild impairment (MCI) subjects compared it with other conventional MRI biomarkers (i.e., hippocampal volume (HV), fraction (HF), brain parenchymal (BPV) (BPF)), which have been used in past as imaging for...
Abstract Background Controversy exists with respect to the etiological role of cerebral small vessel disease (CSVD) in Alzheimer’s (AD). We thus evaluated association between white matter hyperintensity (WMH), an MRI marker CSVD, brain amyloid β (Aβ) and tau burden their plasma markers among subjects varying severity levels cognitive impairment. Methods recruited 84 from CU‐SEEDS (The C hinese U niversity Hong Kong‐ S creening for E arly Alzh imer’s D isea e) study who were stroke‐free had...
Abstract Background We investigated the ability of MRI, plasma, and cognitive biomarkers in detecting preclinical or prodromal Alzheimer’s Disease (AD) who will progress to next syndrome stage continuum. Method 589 subjects with longitudinal data were recruited from Neuroimaging Initiative (ADNI), which included 227 unimpaired (CU) 362 mild impairment (MCI) subjects. Preclinical AD was defined by a low amyloid beta (Aβ) 42 (A+) high phosphorylated ‐tau (p‐tau) (T+) on cerebrospinal fluid...
Abstract Background Although positron emission tomography (PET) or cerebrospinal fluid measurements of amyloid and tau burden are available for the detection Alzheimer’s disease pathology, such methods invasive not easily accessible. Recent studies show that Disease‐resemblance atrophy index (AD‐RAI), an MRI‐based machine learning‐derived biomarker, plasma‐based biomarkers can be used as accurate pathology. We aim to evaluate diagnostic metrics AD‐RAI detecting disease. Method recruited 69...
Abstract Background Controversy exists regarding the etiological role of cerebral small vessel disease (CSVD) in Alzheimer's (AD). We thus evaluated association between brain Aβ/tau burden and white matter hyperintensity (WMH) volume among subjects with varying severity levels cognitive impairment. Method A total 84 stroke‐free (healthy controls [HC]=10; subjective decline [SCD]=32; mild impairment [MCI]=26; dementia =16) were included. All patients underwent structural MRI, 11C‐ PIB,...
Abstract Background Alzheimer’s disease (AD) resemblance atrophy index (AD‐RAI) is an MRI‐based biomarker that was developed using a machine learning technology combines multi‐region MRI features to reflect the characteristic pattern of AD. It validated be accurate in predicting conversion from mild cognitive impairment dementia (1) and identifying AD patients with moderate dementia. We aimed compare performance AD‐RAI various quantitative medial temporal lobe (MTA) measures Method reviewed...